TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01242930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat (7.5 mg/kg)
Description: Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide standard of care
Description: Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide standard of care
Description: Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat (9.4 mg/kg)
Description: Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
Study: NCT03846713

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-thermosoftening
Description: By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thermosoftening
Description: By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
Study: NCT02613325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional photoacoustic microscopy
Description: -Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care surgical excision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single cell photoacoustic microscopy
Study: NCT01678001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xeomin
Description: Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
Study: NCT01689818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: exercise training program which included aerobic exercise for 3 times per week.
Study: NCT05050890

Intervention type: OTHER
Intervention: ctDNA level during neoadjuvant chemotherapy
Description: ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
Study: NCT00891748

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdCD40L
Description: Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
Study: NCT01463436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavone
Description: 100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
Study: NCT04123301

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Theta Burst Stimulation (TBS)
Description: The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
Study: NCT04182789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
Study: NCT02965638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
Study: NCT02849626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: E2007
Study: NCT00505895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
Study: NCT00608452

Intervention type: OTHER
Intervention: Symptom Assessment Scale
Description: * Memorial Symptom Assessment Scale~* History and neurologic examination
Study: NCT03517306

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions

Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study: NCT01214941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be given orally placebo twice a day for 5 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticlopidine
Description: The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticlopidine and itraconazole
Description: The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
Study: NCT01225978

Intervention type: DEVICE
Intervention: GeneInsight Clinic (GIC)
Description: GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing.
Study: NCT03846219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (30 mg/day)
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (45 mg/day)
Description: * Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMU-838 (10 mg/day)
Description: * Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable.
Study: NCT02118857

Intervention type: OTHER
Intervention: Omnivore, vegetarian and vegan subjects.
Description: Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
Study: NCT03812588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
Study: NCT03954444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline Hydrochloride
Description: Test Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhofade Cream, 1%
Description: Reference Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04078334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MATCH
Description: In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATH
Description: In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATH 2.0
Description: In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
Study: NCT01330563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, Ketoconazole
Description: Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, Ketoconazole
Description: Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
Study: NCT02692456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double needle celiac neurolysis (DNCN)
Description: CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single needle celiac neurolysis (SNCN)
Description: CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
Study: NCT03258463

Intervention type: OTHER
Intervention: Change in Texas Law
Description: The change in Texan laws occurring from July 2013-January 2014
Study: NCT00671814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701
Description: TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid
Description: Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
Study: NCT03721237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBC-assisted
Description: After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds).
Study: NCT03283618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conferencing Group
Study: NCT02700295

Intervention type: DEVICE
Intervention: Orthokeratology lens
Study: NCT00305747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DIM
Description: 75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
Study: NCT03679429

Intervention type: DEVICE
Intervention: NBI Function
Description: In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
Study: NCT03018457

Intervention type: DEVICE
Intervention: ISQ
Description: Measured by Osstell.
Study: NCT00818571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Matching healthy volunteers receiving 25 mg vildagliptin once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Matching healthy volunteers receiving 50 mg vildagliptin once daily
Study: NCT04176445

Intervention type: DEVICE
Group type: OTHER
Intervention: Orthostatic board posture
Description: Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes

Intervention type: DEVICE
Group type: OTHER
Intervention: Orthostatic board posture
Description: Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: Bedside sitting posture
Description: Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Bedside sitting posture
Description: Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
Study: NCT02034552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
Study: NCT02486367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Standard ADP receptor blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: High potency ADP receptor blockade
Study: NCT03123055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-701
Description: B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-701
Description: B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
Study: NCT00795353

Intervention type: DRUG
Intervention: Amevive exposure
Description: Commercial alefacept prescribed by Physician
Study: NCT04462757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: 100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe
Description: 100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
Study: NCT02435641

Intervention type: OTHER
Intervention: Questionnaires
Description: All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
Study: NCT00565058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
Study: NCT04202549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial cocktail therapy
Description: Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
Study: NCT00631540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula Balloon-Expandable Stent
Description: renal artery stenting